目的 探討紅花黃色素聯(lián)合美托洛爾治療冠心病心力衰竭的臨床療效。方法 選取2016年7月-2017年7月在商丘市第一人民醫(yī)院進(jìn)行治療的冠心病心力衰竭患者82例，按照用藥的差別分為對(duì)照組（41例）和治療組（41例）。對(duì)照組口服酒石酸美托洛爾片，起始劑量6.25 mg/次，2次/d，可耐受情況下，隔周增加6.25~12.5 mg/次，2次/d，最大劑量不超過(guò)300~400 mg/d；治療組在對(duì)照組的基礎(chǔ)上靜脈滴注注射用紅花黃色素，100 mg加入100 mL生理鹽水，1次/d。兩組均治療2周。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者心功能指標(biāo)和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組臨床有效率為78.05%，顯著低于治療組的95.12%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左心室收縮末內(nèi)徑（LVEDD）、左心室收縮末容量（LVESV）、左心室舒張末內(nèi)徑（LVESD）均明顯下降，左心室射血分?jǐn)?shù)（LVEE）明顯升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些心功能指標(biāo)明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組血清超敏C反應(yīng)蛋白（hs-CRP）、N-末端B型腦鈉肽前體（NT-proBNP）、肌鈣蛋白T（cTnT）、GDF-15水平均顯著降低（P<0.05），且治療組這些血清學(xué)指標(biāo)明顯低于對(duì)照組（P<0.05）。結(jié)論 紅花黃色素聯(lián)合美托洛爾治療冠心病心力衰竭有利于患者心功能改善，降低心肌重塑風(fēng)險(xiǎn)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Safflor Yellow for injection combined with metoprolol in treatment of heart failure of coronary heart disease. Methods Patients (82 cases) with heart failure of coronary heart disease in the First People's Hospital of Shangqiu from July 2016 to July 2017 were divided into control (41 cases) and treatment (41 cases) groups according to different treatment. Patients in the control group were po administered with Metoprolol Tartrate Tablets, the initial dose was 6.25 mg/time, twice daily, then fortnightly increased with 6.25-12.5 mg/time, twice daily, and the maximum dose was less than 300-400 mg/d. Patients in the treatment group were iv administered with Safflor Yellow for injection on the basis of the control group, 10 mg added into normal saline 100 mL, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.05%, which was significantly lower than 95.12% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the LVEDD, LVESV and LVESD levels in two groups were significantly decreased, the LVEE levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the cardiac function indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the serum hs-CRP, NT-proBNP, cTnT and GDF-15 levels in two groups were significantly decreased (P<0.05), and the serological indexes in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Safflor Yellow for injection combined with metoprolol in treatment of heart failure of coronary heart disease can significantly improve cardiac function and reduce the myocardial remodeling risk, which has a certain clinical application value.